AptaBio Therapeutics Inc. (293780.KQ)

KRW 6500.0

(-3.56%)

Market Cap (In KRW)

174.72 Billion

Revenue (In KRW)

323.86 Million

Net Income (In KRW)

-12.06 Billion

Avg. Volume

746.06 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4930.0-15490.0
PE
-
EPS
-
Beta Value
1.962
ISIN
KR7293780003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Jin Lee Soo
Employee Count
-
Website
http://www.aptabio.com
Ipo Date
2019-06-12
Details
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.